Enzymotec (Enzymotec) Cash And Cash Equivalents : $10.59 Mil (As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Cash And Cash Equivalents?

Enzymotec's quarterly cash and cash equivalents declined from Mar. 2017 ($8.16 Mil) to Jun. 2017 ($7.77 Mil) but then increased from Jun. 2017 ($7.77 Mil) to Sep. 2017 ($10.59 Mil).

Enzymotec's annual cash and cash equivalents declined from Dec. 2014 ($30.29 Mil) to Dec. 2015 ($21.99 Mil) and declined from Dec. 2015 ($21.99 Mil) to Dec. 2016 ($7.58 Mil).

Enzymotec Cash And Cash Equivalents Historical Data

The historical data trend for Enzymotec's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Cash And Cash Equivalents Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Cash And Cash Equivalents

Get a 7-Day Free Trial

2.73

74.43

30.29

21.99

7.58

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Cash And Cash Equivalents	Get a 7-Day Free Trial															10.64	7.58	8.16	7.77	10.59

Enzymotec Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Enzymotec (NAS:ENZY) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Enzymotec Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Enzymotec's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015